You are here: Home: Audio Program Guide: CCU GI Think Tank 2007: CCU GI Think Tank 2007 - Audio
 
 

Go to interview with Daniel G Haller, MD
Go to interview with Alan P Venook, MD
Go to interview with Axel Grothey, MD
Go to interview with Norman Wolmark, MD
Go to interview with Richard M Goldberg, MD
Go to interview with Neal J Meropol, MD
Go to interview with Howard S Hochster, MD
Go to interview with Axel Grothey, MD
Go to interview with Richard M Goldberg, MD

  To listen to individual tracks, click the on the headphone.
To download tracks, right-click on the one you wish to download.
Halley, MD Daniel G Haller, MD
Professor of Medicine
Abramson Cancer Center at the
University of Pennsylvania
Philadelphia, Pennsylvania


  
  Click here to download the entire interview  
Track 1 Use of oxaliplatin as a radiosensitizer, systemic therapy or both
Track 2 NSABP-R-04: Preoperative radiation therapy and capecitabine or 5-FU with or without oxaliplatin for operable rectal cancer
Track 3 Use of preoperative versus postoperative chemotherapy in rectal cancer
Track 4 Importance of preoperative staging in the determination of optimal therapy for rectal cancer
Track 5 Preoperative chemoradiation therapy with oxaliplatin for select patients with locally advanced rectal cancer
Track 6 Rationale for NSABP-R-04 design
Track 7 Preoperative staging and the use of neoadjuvant chemoradiation therapy versus postoperative chemotherapy
Track 8 Incorporating biologic agents in preoperative therapy of rectal cancer
Track 9 Use of preoperative oxaliplatin-containing chemoradiation therapy for rectal cancer
     
Vennok, MD Alan P Venook, MD
Professor of Clinical Medicine
Associate Chief
Division of Medical Oncology
University of California
San Francisco
San Francisco, California


  
  Click here to download the entire interview  
Track 1 Use of bevacizumab for patients with prior arterial events
Track 2 Potential mechanisms underlying bevacizumab-associated arterial thromboembolic events
Track 3 Surgery after treatment with bevacizumab
Track 4 Reversible posterior leukoencephalopathy syndrome (RPLS) and bevacizumab
Track 5 Dose of bevacizumab, use of aspirin and risk of thromboembolic events or bleeding
Track 6 Balancing risks and benefits of bevacizumab
Track 7 Perspectives on the long-term use of bevacizumab in the adjuvant and metastatic settings
Track 8 Treatment of bevacizumab-associated hypertension
     
Grothey, MD Axel Grothey, MD
Senior Associate Consultant
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota


  
  Click here to download the entire interview  
Track 1 Planned “holidays” from oxaliplatin or irinotecan during treatment with FOLFOX or FOLFIRI
Track 2 Incorporation of biologic therapies in chemotherapy-free intervals and maintenance strategies
Track 3 Complete treatment-free intervals versus maintenance therapy and the role of biologic agents
Track 4 Considerations in defining the end of treatment holidays
Track 5 Peripheral neuropathy and the decision to discontinue or reintroduce oxaliplatin
Track 6 Failure to utilize maintenance therapy: Impact on progression-free survival in XELOX-1/NO16966

     
Wolmark, MD Norman Wolmark, MD
Professor and Chairman
Department of Human Oncology
Allegheny General Hospital
Professor, Drexel University
College of Medicine
Chairman, National Surgical
Adjuvant Breast and Bowel Project
Pittsburgh, Pennsylvania		  
  Click here to download the entire interview  
Track 1 Incidence and treatment of patients presenting with synchronous primary and metastatic colon cancer
Track 2 NSABP-C-10: FOLFOX6 with bevacizumab for patients with unresectable Stage IV colon cancer and a synchronous asymptomatic primary tumor
Track 3 Clinical endpoints in NSABP-C-10: Events related to the intact primary tumor
Track 4 Treatment for patients with an intact primary tumor and synchronous metastatic disease
Track 5 Treatment approach for patients with rectal cancer and simultaneous metastatic disease
Track 6 Considerations in the addition of cetuximab to first-line chemotherapy

     
Goldberg, MD Richard M Goldberg, MD
Professor and Chief
Division of Hematology/Oncology
Associate Director
University of North Carolina
Lineberger Comprehensive
Cancer Center
Chapel Hill, North Carolina		  
  Click here to download the entire interview  
Track 1 Selection and use of adjuvant chemotherapy for older patients
Track 2 Chemotherapy tolerance in octogenarians
Track 3 Case discussion: A 92-year-old man with T3N2 (10 positive nodes) colon cancer
Track 4 FOLFOX versus FLOX in the adjuvant treatment of older patients with colorectal cancer

     
Meropol, MD Neal J Meropol, MD
Director, Gastrointestinal
Cancer Program
Director, Gastrointestinal Tumor Risk
Assessment Program
Divisions of Medical Science and
Population Science
Fox Chase Cancer Center
Philadelphia, Pennsylvania		  
  Click here to download the entire interview  
Track 1 Adjuvant chemotherapy for patients with Stage II colon cancer
Track 2 Differences in physician perceptions of benefit from adjuvant therapy in breast and colon cancer
Track 3 Patients’ perceptions of potential benefit from adjuvant therapy
audio
Track 4 Patients’ expectations regarding toxicity and side effects of chemotherapy
Track 5 Risk-benefit considerations and impact on patient preferences for adjuvant chemotherapy
Track 6 Survey of patients’ and physicians’ perspectives on preferences for adjuvant therapy

Hochster, MD Howard S Hochster, MD
Professor of Medicine and
Clinical Pharmacology
NYU Cancer Institute
New York, New York


  
  Click here to download the entire interview  
Track 1 Preoperative therapy for patients undergoing potentially curative resection of hepatic metastases
Track 2 Chemotherapy with bevacizumab and an anti-EGFR antibody or cetuximab for potentially resectable metastatic disease
Track 3 Therapeutic approach for patients with “borderline resectable” metastatic disease
Track 4 Clinical trials evaluating biologic doublets in the metastatic setting
Track 5 Potential impact of converting unresectable hepatic metastases to resectable disease
Track 6 Novel biologic strategies and agents in colorectal cancer
Track 7 Tumor location and vascularity and the resectability of hepatic metastases
Track 8 Use of FOLFOX with bevacizumab plus cetuximab for potentially resectable metastatic disease
Track 9 Therapeutic options for patients with peritoneal metastases and liver disease

Gothey, MD Axel Grothey, MD
Senior Associate Consultant
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota


  
  Click here to download the entire interview  
Track 1 Incorporation of oxaliplatin in preoperative chemoradiation therapy for select patients with rectal cancer
Track 2 Use of first-line chemotherapy/bevacizumab for patients with recent arterial events
Track 3 Bevacizumab-associated arterial thromboembolic events
Track 4 FOLFOX with bevacizumab for asymptomatic patients with simultaneous primary and metastatic colon cancer
Track 5 Use of oxaliplatin-containing adjuvant chemotherapy for elderly patients
Track 6 Adjuvant chemotherapy for patients with Stage II colon cancer
Track 7 Preoperative chemotherapy with bevacizumab and an anti-EGFR monoclonal antibody in the treatment of resectable liver metastases

Goldberg, MD Richard M Goldberg, MD
Professor and Chief
Division of Hematology/Oncology
Associate Director
University of North Carolina
Lineberger Comprehensive
Cancer Center
Chapel Hill, North Carolina


  
  Click here to download the entire interview  
Track 1 Addition of oxaliplatin to preoperative chemotherapy in the treatment of rectal cancer
Track 2 Use of bevacizumab for patients with prior arterial events
Track 3 Management of hypertension in patients treated with bevacizumab
Track 4 Clinical approach for patients presenting with synchronous primary and metastatic colorectal cancer
Track 5 Chemotherapy with doublet monoclonal antibodies for patients with potentially curable metastatic disease